论文部分内容阅读
为探讨性激素受体与肾癌生物学特性的关系及肾癌患者内分泌治疗的实验依据，采用亲和酶标法测定29例肾癌及其癌旁肾织织和12例正常肾组织标本的孕激素受体（PR）和雌激素受体（ER）。结果发现ER及PR均为胞浆型受体，肾癌PR及ER阳性率明显低于癌旁肾组织和正常肾组织（P＜0．05），癌旁肾组织和正常肾组织间则无明显差异（P＞0．05），Ⅰ期肾癌组织PR阳性率（50．0％）明显高于Ⅲ～Ⅳ期肾癌组织阳性率（9．0％）（P＜0．05），肾颗粒细胞癌与透明细胞癌之间及男女患者之间PR、ER表达均无差异（P＞0．05）。提示PR阳性率与肾癌分期紧密相关，可作为观察预后和随访的参考指标。鉴于肾癌组织PR阳性率低，强调孕激素治疗的个体化。
In order to explore the relationship between the sex hormone receptor and the biological characteristics of renal cell carcinoma and the experimental basis of endocrine therapy in patients with renal cell carcinoma, the pregnancy of renal cell carcinoma and its adjacent normal kidney tissue and 12 cases of normal renal tissue Hormone receptor (PR) and estrogen receptor (ER). The results showed that both ER and PR were cytoplasmic receptors, the positive rate of PR and ER in renal cell carcinoma was significantly lower than that in paracancer renal tissues and normal renal tissues (P <0.05), while there was no difference between adjacent renal tissues and normal renal tissues (P> 0.05). The positive rate of PR in stage I renal carcinoma (50.0%) was significantly higher than that in stage III-IV renal carcinoma (9.0%) (P <0.05) There was no difference in PR and ER between renal cell carcinoma and clear cell carcinoma and between male and female patients (P> 0.05). Prompted PR positive rate and renal cell carcinoma staging are closely related, can be used as a reference to observe the prognosis and follow-up. In view of the low positive rate of PR in renal cell carcinoma, emphasis is placed on the individualization of progestin therapy.